Sumita Ray was named Corporate Secretary of Cue Biopharma, Inc., effective June 1, 2026. As of November 6, 2026, Cue Biopharma, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 1, 2026 to June 2, 2026, naming 3 appointments (Form 8-K, June 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Cue Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Cue Biopharma, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-01 to 2026-06-02. They name 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as Cue Biopharma, Inc. files it.
Also on the record for Cue Biopharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 8, 2026 | Stake report, Schedule 13G/A, by Mark E. Strome | 8.5% of the class | 5%+ stakes | Source |
| August 21, 2026 | Stake report, Schedule 13D, by Shao-Lee Lin | 6.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by DRIEHAUS CAPITAL MANAGEMENT LLC | 6.96% of the class | 5%+ stakes | Source |
| July 22, 2026 | Form D, private offering | $50M sold | Form D page | Source |
| May 14, 2026 | Form D, private offering | $30M sold | Form D page | Source |
Selling to them or working with them? See who runs Cue Biopharma, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cue Biopharma, Inc. and the records around it.
Cue Biopharma, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Company profile and every filing Jul 2026
- Form D filing Jul 2026
- Form D filing May 2026
- Who owns it
Companies that share a holder
- Mark E. Strome also filed stake reports on 2 other companies: HeartBeam, Inc. (Aug 2026), Zivo Bioscience (Feb 2026)
- DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies: Cardinal Infrastructure Group Inc. (Aug 2026), Definium Therapeutics, Inc. (Aug 2026), Frequency Electronics, Inc. (Aug 2026)
Watch Cue Biopharma, Inc.
Get an email when Cue Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cue Biopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cue Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cue Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-02 | In | Corporate Secretary | 2026-06-01 | 8-K, 2026-06-02 | |
| 2026-06-02 | In | Vice President, Principal Accounting Officer | 2026-06-01 | 8-K, 2026-06-02 | |
| 2026-05-01 | In | President and Chief Executive Officer | 8-K, 2026-05-01 |
Who leads Cue Biopharma, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Vice President, Principal Accounting Officer: Michael Meluzio, appointed, effective 2026-06-01 (filed 2026-06-02).
- Corporate Secretary: Sumita Ray, appointed, effective 2026-06-01 (filed 2026-06-02).
- President and Chief Executive Officer: Lee Lin, appointed (filed 2026-05-01).
New leaders reset buying decisions — get the Full Report on Cue Biopharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Cue Biopharma, Inc. (free up to 3)
Find people with the same kind of experience as the Corporate Secretary at Cue Biopharma, Inc., with the record behind each one.
Find candidates like Corporate Secretary at Cue Biopharma, Inc.Every change, in the filing's words
Appointed: Sumita Ray, Corporate Secretary, effective 2026-06-01
(b) On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company's Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.
Appointed: Michael Meluzio, Vice President, Principal Accounting Officer, effective 2026-06-01
(c) On June 1, 2026, the Board appointed Michael Meluzio as the Company's Vice President, Principal Accounting Officer, to serve as the Company's principal accounting officer, effective June 1, 2026.
- (b) On May 29, 2026, Cue Biopharma, Inc. (the "Company") and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the "Board") and as members of the committees of the Board on which they serve, effective immediately.
- Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot's respective resignations were not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- The Board would like to thank Messrs. Keiner, Morich and Verheyen and Ms. Broadfoot for their years of dedicated service to the Company.
- Ms. Ray succeeds Colin Sandercock, M.S.E, J.D., who served as the Company's Senior Vice President, General Counsel and Secretary.
- Mr. Sandercock will continue to serve as the Company's Senior Vice President, Intellectual Property.
- Ms. Ray has been in the biotech industry for over 25 years and has held positions as Chief Legal & Compliance Officer and Corporate Secretary for over a decade at various publicly traded companies.
- Most recently she served as Chief Legal, Compliance & Administrative Officer and Corporate Secretary at Vaxxinity (Nasdaq: VAXX), a formerly public biotechnology company from October 2023 through March 2025.
Appointed: Lee Lin, President and Chief Executive Officer
In connection with her appointment as President and Chief Executive Officer, Dr. Lin will serve as the Company's principal executive, accounting and financial officer.
- 2026 Inducement Stock Incentive Plan On April 27, 2026, the Board adopted the Company's 2026 Inducement Stock Incentive Plan (the "Inducement Plan"), pursuant to which the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stock-based awards, and performance awards with respect to an aggregate of 3,000,000 shares of Common Stock.
- Awards under the Inducement Plan may only be granted to new employees who were not previously an employee or director of the Company or are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to the individual's entering into employment with the Company in accordance with the requirements of Nasdaq Listing Rule 5635(c)(4).
- President and Chief Executive Officer Appointment and Resignation On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company's President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026 (the "Effective Date").
Cue Biopharma, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Cue Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.